Inhibiting SSBP1 enhances ferroptosis and improves the effectiveness of sorafenib treatment for liver cancer.

ABSTRACT: Liver cancer is the third leading cause of cancer‑related mortality globally, with increasing morbidity and mortality rates. Sorafenib, a multi‑kinase inhibitor, is an effective first‑line therapy for late‑stage liver cancer. However, its effectiveness is hindered by low responsiveness, high drug resistance and significant side effects. The progression and metastasis of liver cancer are associated with alterations in mitochondrial metabolism, including mitochondrial stress responses and defects in oxidative phosphorylation, which are involved in the increased production of reactive oxygen species. Targeting mitochondrial biogenesis and bioenergetics presents a promising therapeutic strategy. Bioinformatics analysis (integrated analysis of The Cancer Genome Atlas, mitochondrial genomes, liv

SUBMITTER: Li S 

PROVIDER: S-EPMC12339803 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature